A Study of DII235 in Adults With Elevated Lipoprotein(a)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 234 participants.

Also called NCT07235046

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 234 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07235046
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, China, Germany, Japan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07235046. Randomized; double masking; primary purpose treatment. Start 2025-12-02 (actual); primary completion 2027-04-26 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of DII235 in Adults With Elevated Lipoprotein(a)
Condition
Lipoprotein Disorder
Intervention (Drug)
DII235
Intervention (Drug)
Saline
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07235046
Content hash
4a13cd82c3724bfe081d188982cecf156ea7855fb0270d2e0144cafc2ec9a652